EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Inhibition of UBE2C Promotes Parkin‐Mediated K63‐Linked Ubiquitination of TOP2A to Induce Senescence and Increase Sensitivity of Doxorubicin in Breast Cancer

Yihui Yang, Wan Li, Hong Yang, Fang Xu, Sen Zhang, Wanxin Cao, Xiaoxue Li, Xu Zhang, Xiangyin Chi, Hongquan Wang, Guanhua Du, Yumin Wang und 1 weitere

Advanced Science · 2025-08 · 12 (32)

DOI: 10.1002/advs.202417348 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Science, online erschienen am 29.07.2025. Verfasst von Yihui Yang und 12 weiteren Autor:innen. Beteiligte Einrichtung: The State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Beijing, 100050, China. Hauptthemen laut MEDLINE: Doxorubicin, Ubiquitin-Conjugating Enzymes, Breast Neoplasms, Ubiquitin-Protein Ligases. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Beijing Natural Science Foundation, Chinese Academy of Medical Sciences Initiative for Innovative Medicine, Natural Science Foundation of Beijing Municipality.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Breast cancer is now the second most commonly diagnosed cancer and the most common female malignancy. Chemotherapy‐based adjuvant therapy after surgery and neoadjuvant therapy before surgery are cornerstones of breast cancer treatment. Doxorubicin is one of the most commonly used anthracycline chemotherapy treatments for breast cancer; however, doxorubicin resistance is a major barrier to its clinical use. Therefore, there is an urgent need to discover new targets to overcome doxorubicin resistance in breast cancer. Ubiquitin‐conjugating enzyme 2C (UBE2C) is an E2 ubiquitin‐conjugating enzyme that catalyzes the assembly of K11‐linked ubiquitin chains. In recent years, dysregulation of UBE2C has been implicated in a variety of cancers, including breast cancer; however, the underlying mechanisms remain unclear. In the present study, UBE2C was found to be markedly upregulated in breast cancer and transcriptionally regulated by FOXM1. Inhibition of UBE2C suppressed proliferation and induced senescence in breast cancer cells. Moreover, the inhibition of UBE2C promoted Parkin‐mediated K63‐linked ubiquitination of TOP2A, leading to its proteasomal degradation and thus sensitizing breast cancer cells to doxorubicin. The study reveals that UBE2C is a critical regulator of breast cancer cell proliferation, senescence, and sensitivity to doxorubicin.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DoxorubicinUbiquitin-Conjugating EnzymesBreast NeoplasmsUbiquitin-Protein LigasesPoly-ADP-Ribose Binding ProteinsDNA Topoisomerases, Type IIHumansFemaleUbiquitinationDrug Resistance, NeoplasmCell Line, TumorCellular SenescenceCell Proliferation

Stichwörter der Autor:innen

TOP2AUBE2Cbreast cancerdoxorubicin sensitivitysenescence

Substanzen

DoxorubicinUbiquitin-Conjugating EnzymesUbiquitin-Protein Ligasesparkin proteinUBE2C protein, humanPoly-ADP-Ribose Binding ProteinsDNA Topoisomerases, Type IITOP2A protein, human

Autor:innen und Institutionen

  • The State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Beijing, 100050, China.
  • Beijing Key Laboratory of Innovative Drug Discovery and Polymorphic Druggability Research for Cerebrovascular Diseases, Institute of Materia Medica, Chinese Academy of Medical Science and Peking Union Medical College, B…
  • Department of Geriatrics, Aerospace Center Hospital, Peking University Aerospace School of Clinical Medicine, Beijing, 100049, China.
  • Department of Respiratory and Critical Care Medicine, Aerospace Center Hospital, Peking University Aerospace School of Clinical Medicine, Beijing, 100049, China.

ORCID-Profile: Jinhua Wang

Förderung

  • Beijing Natural Science Foundation
  • Chinese Academy of Medical Sciences Initiative for Innovative Medicine
  • Natural Science Foundation of Beijing Municipality

Zitieren

APA

Yang, Y., Li, W., Yang, H., Xu, F., Zhang, S., Cao, W., Li, X., Zhang, X., Chi, X., Wang, H., Du, G., Wang, Y., & Wang, J. (2025). Inhibition of UBE2C Promotes Parkin‐Mediated K63‐Linked Ubiquitination of TOP2A to Induce Senescence and Increase Sensitivity of Doxorubicin in Breast Cancer. Advanced Science, 12(32). https://doi.org/10.1002/advs.202417348

Vancouver

Yang Y, Li W, Yang H, Xu F, Zhang S, Cao W, et al. Inhibition of UBE2C Promotes Parkin‐Mediated K63‐Linked Ubiquitination of TOP2A to Induce Senescence and Increase Sensitivity of Doxorubicin in Breast Cancer. Advanced Science. 2025;12(32). doi:10.1002/advs.202417348

BibTeX
@article{Yang2025,
  author = {Yang, Yihui and Li, Wan and Yang, Hong and Xu, Fang and Zhang, Sen and Cao, Wanxin and Li, Xiaoxue and Zhang, Xu and Chi, Xiangyin and Wang, Hongquan and Du, Guanhua and Wang, Yumin and Wang, Jinhua},
  title = {Inhibition of UBE2C Promotes Parkin‐Mediated K63‐Linked Ubiquitination of TOP2A to Induce Senescence and Increase Sensitivity of Doxorubicin in Breast Cancer},
  journal = {Advanced Science},
  year = {2025},
  volume = {12},
  number = {32},
  doi = {10.1002/advs.202417348}
}
Kostenlos starten →